Annual accounts receivable:
$775.73M+$162.00M(+26.40%)Summary
- As of today (September 18, 2025), AMRX annual accounts receivable is $775.73 million, with the most recent change of +$162.00 million (+26.40%) on December 31, 2024.
- During the last 3 years, AMRX annual accounts receivable has risen by +$111.97 million (+16.87%).
- AMRX annual accounts receivable is now at all-time high.
Performance
AMRX Accounts receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly accounts receivable:
$807.64M+$53.40M(+7.08%)Summary
- As of today (September 18, 2025), AMRX quarterly accounts receivable is $807.64 million, with the most recent change of +$53.40 million (+7.08%) on June 30, 2025.
- Over the past year, AMRX quarterly accounts receivable has increased by +$37.77 million (+4.91%).
- AMRX quarterly accounts receivable is now at all-time high.
Performance
AMRX Quarterly accounts receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Accounts receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
AMRX Accounts receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +26.4% | +4.9% |
| 3 y3 years | +16.9% | +17.0% |
| 5 y5 years | +28.4% | +38.3% |
AMRX Accounts receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +26.4% | at high | +48.0% |
| 5 y | 5-year | at high | +28.4% | at high | +51.9% |
| alltime | all time | at high | +2441.1% | at high | +884.3% |
AMRX Accounts receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $807.64M(+7.1%) |
| Mar 2025 | - | $754.24M(-2.8%) |
| Dec 2024 | $775.73M(+26.4%) | $775.73M(+3.7%) |
| Sep 2024 | - | $748.05M(-2.8%) |
| Jun 2024 | - | $769.87M(+15.1%) |
| Mar 2024 | - | $668.96M(+9.0%) |
| Dec 2023 | $613.73M(-17.3%) | $613.73M(-11.2%) |
| Sep 2023 | - | $690.95M(+2.4%) |
| Jun 2023 | - | $674.74M(+23.6%) |
| Mar 2023 | - | $545.76M(-26.5%) |
| Dec 2022 | $741.79M(+11.8%) | $742.29M(+17.7%) |
| Sep 2022 | - | $630.43M(-8.7%) |
| Jun 2022 | - | $690.19M(+27.9%) |
| Mar 2022 | - | $539.48M(-18.7%) |
| Dec 2021 | $663.76M(+3.7%) | $663.76M(+5.5%) |
| Sep 2021 | - | $629.26M(-3.7%) |
| Jun 2021 | - | $653.14M(+22.8%) |
| Mar 2021 | - | $531.70M(-17.0%) |
| Dec 2020 | $640.30M(+5.9%) | $640.30M(-9.6%) |
| Sep 2020 | - | $708.04M(+21.3%) |
| Jun 2020 | - | $583.90M(-19.4%) |
| Mar 2020 | - | $724.41M(+19.9%) |
| Dec 2019 | $604.39M(+16.7%) | $604.39M(+16.7%) |
| Sep 2019 | - | $518.11M(-18.4%) |
| Jun 2019 | - | $634.67M(-0.9%) |
| Mar 2019 | - | $640.21M(+23.6%) |
| Dec 2018 | $517.89M(+47.4%) | $517.89M(-19.2%) |
| Sep 2018 | - | $641.03M(+2.3%) |
| Jun 2018 | - | $626.49M(+78.3%) |
| Dec 2017 | $351.37M(+36.5%) | $351.37M(+36.5%) |
| Dec 2016 | $257.37M | - |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2016 | - | $257.37M(+7.4%) |
| Sep 2016 | - | $239.59M(+0.9%) |
| Jun 2016 | - | $237.45M(+10.7%) |
| Mar 2016 | - | $214.45M(-33.9%) |
| Dec 2015 | $324.45M(+108.8%) | $324.45M(+42.0%) |
| Sep 2015 | - | $228.50M(-14.3%) |
| Jun 2015 | - | $266.64M(+34.6%) |
| Mar 2015 | - | $198.07M(+27.4%) |
| Dec 2014 | $155.43M(+37.6%) | $155.43M(+2.1%) |
| Sep 2014 | - | $152.29M(-47.4%) |
| Jun 2014 | - | $289.25M(+17.4%) |
| Mar 2014 | - | $246.37M(+118.0%) |
| Dec 2013 | $112.99M(+22.5%) | $112.99M(-53.7%) |
| Sep 2013 | - | $244.08M(+24.4%) |
| Jun 2013 | - | $196.20M(+72.7%) |
| Mar 2013 | - | $113.61M(+23.2%) |
| Dec 2012 | $92.25M(-40.0%) | $92.25M(-5.6%) |
| Sep 2012 | - | $97.77M(-31.8%) |
| Jun 2012 | - | $143.45M(+20.4%) |
| Mar 2012 | - | $119.18M(-22.5%) |
| Dec 2011 | $153.77M(+87.4%) | $153.77M(+45.1%) |
| Sep 2011 | - | $106.00M(-12.4%) |
| Jun 2011 | - | $121.07M(+28.4%) |
| Mar 2011 | - | $94.28M(+14.9%) |
| Dec 2010 | $82.05M(-55.9%) | $82.05M(-14.1%) |
| Sep 2010 | - | $95.57M(-29.7%) |
| Jun 2010 | - | $136.01M |
| Dec 2009 | $185.85M(+446.5%) | - |
| Dec 2008 | $34.01M(-34.0%) | - |
| Dec 2007 | $51.50M(-16.8%) | - |
| Dec 2006 | $61.92M(+102.8%) | - |
| Dec 2005 | $30.53M | - |
FAQ
- What is Amneal Pharmaceuticals, Inc. annual accounts receivable?
- What is the all time high annual accounts receivable for Amneal Pharmaceuticals, Inc.?
- What is Amneal Pharmaceuticals, Inc. annual accounts receivable year-on-year change?
- What is Amneal Pharmaceuticals, Inc. quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Amneal Pharmaceuticals, Inc.?
- What is Amneal Pharmaceuticals, Inc. quarterly accounts receivable year-on-year change?
What is Amneal Pharmaceuticals, Inc. annual accounts receivable?
The current annual accounts receivable of AMRX is $775.73M
What is the all time high annual accounts receivable for Amneal Pharmaceuticals, Inc.?
Amneal Pharmaceuticals, Inc. all-time high annual accounts receivable is $775.73M
What is Amneal Pharmaceuticals, Inc. annual accounts receivable year-on-year change?
Over the past year, AMRX annual accounts receivable has changed by +$162.00M (+26.40%)
What is Amneal Pharmaceuticals, Inc. quarterly accounts receivable?
The current quarterly accounts receivable of AMRX is $807.64M
What is the all time high quarterly accounts receivable for Amneal Pharmaceuticals, Inc.?
Amneal Pharmaceuticals, Inc. all-time high quarterly accounts receivable is $807.64M
What is Amneal Pharmaceuticals, Inc. quarterly accounts receivable year-on-year change?
Over the past year, AMRX quarterly accounts receivable has changed by +$37.77M (+4.91%)